People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Pharmaceuticals, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2013 |
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| Seventh Sense Biosystems, Inc. | — | Biotechnology | Series B | $62.9M | $732.6M | 2011 |
| Living Proof Inc | — | Other | Series B | $39.0M | $498.4M | 2009 |
PETER HUTT at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside PETER HUTT on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 4 | 36 |
| Noubar Afeyan | 2 | 9 |
| Lorence Kim | 2 | 5 |
| Lee Babiss | 2 | 5 |
| John Mendlein | 2 | 4 |
| Stephane Bancel | 2 | 4 |
| Henri Termeer | 2 | 3 |
| Peter Barton Hutt | 1 | 14 |
| Robert S Langer | 1 | 14 |
| Alan Crane | 1 | 9 |
| Doug Cole | 1 | 6 |
| Jonathan Flint | 1 | 6 |
| Harry Wilcox | 1 | 6 |
| NEIL EXTER | 1 | 5 |
| Robert Carpenter | 1 | 5 |
| Timothy Richards | 1 | 4 |
| Amir H. Nashat | 1 | 3 |
| R. ROX ANDERSON | 1 | 3 |
| HOWARD WEISMAN | 1 | 3 |
| Theo Melas-Kyriazi | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.